Form 4: ResMed CEO Exercises Options, Sells Shares Under 10b5-1 Plan

ResMed CEO Michael J. Farrell exercised stock options and sold 8,009 shares of common stock for a significant profit, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael J. Farrell, Chief Executive Officer of ResMed Inc. (RMD), engaged in a transaction involving the company's common stock on October 7, 2025.
• The transaction was conducted under a Rule 10b5-1 plan adopted on October 31, 2024.
• Farrell exercised options to acquire 8,009 shares of ResMed Common Stock at an exercise price of $101.64 per share.
• Concurrently, he sold 8,009 shares of ResMed Common Stock at a weighted average sale price of $282.8483 per share, with individual trades ranging from $280.95 to $283.90.
• Following these transactions, Farrell directly beneficially owns 467,792 shares of ResMed Common Stock and indirectly owns 2,090 shares through the Lisette and Michael Farrell Family Trust.
• He also beneficially owns 8,011 derivative securities (options) after the reported transactions.

Sentiment

Score: 6

Explanation: The transaction reflects a planned liquidity event for the CEO, realizing significant value from stock options. While insider selling can sometimes be viewed negatively, the pre-arranged 10b5-1 plan mitigates concerns about opportunistic timing. The substantial profit indicates positive past performance of the company's stock.

Positives

• The CEO realized a substantial profit from exercising options and selling shares, indicating personal financial benefit from the company's stock performance.
• The transaction was executed under a pre-arranged Rule 10b5-1 plan, which suggests a planned liquidity event rather than a reaction to new, undisclosed information.

Negatives

• The sale of shares by a Chief Executive Officer, even under a 10b5-1 plan, could be interpreted by some investors as a signal of reduced confidence, although this is not necessarily the case for planned transactions.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the CEO's sale of shares as a signal, though the 10b5-1 plan suggests it's a pre-planned liquidity event rather than a reaction to new information. The significant profit realized by the CEO could be seen positively as a reward for performance.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction by the CEO, Michael J. Farrell, involving the exercise of options and subsequent sale of shares. While the CEO realized a substantial profit, which is a positive for the individual, the transaction itself does not provide new fundamental information about ResMed Inc.'s operational performance or future prospects. As such, it does not warrant a change in investment recommendation based solely on this disclosure. Investors should continue to 'hold' and monitor the company's financial results and strategic developments.

Keywords

ResMed, RMD, Michael J. Farrell, CEO, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Beneficial Ownership